How many drugs treat Localization-related epilepsy?

Drug Landscape tracks 6 marketed treatments for Localization-related epilepsy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/localization-related-epilepsy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Localization-related epilepsy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Localization-related epilepsy (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Localization-related epilepsy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tegretol	carbamazepine	Novartis AG (originally Geigy)	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
Mysoline	PRIMIDONE	Bausch Health	Anti-epileptic Agent [EPC]	Transient receptor potential cation channel subfamily M member 3	1954-01-01
Phenytoin Sodium	PHENYTOIN	Viatris	Anti-epileptic Agent	Sodium channel protein type 2 subunit alpha	1953-01-01
Dilantin	Phenytoin Sodium	Pfizer	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Mesantoin	MEPHENYTOIN	Novartis	Anti-epileptic Agent	Sodium channel alpha subunit	1946-01-01
Carbamazepin	Carbamazepin	Enanta Pharmaceuticals, Inc		Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bausch Health · 1 drug in Localization-related epilepsy
Enanta Pharmaceuticals, Inc · 1 drug in Localization-related epilepsy
Novartis · 1 drug in Localization-related epilepsy
Novartis AG (originally Geigy) · 1 drug in Localization-related epilepsy
Pfizer · 1 drug in Localization-related epilepsy
Viatris · 1 drug in Localization-related epilepsy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Localization-related epilepsy:

Cite this brief

Drug Landscape (2026). Localization-related epilepsy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/localization-related-epilepsy. Accessed 2026-06-10.

Localization-related epilepsy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing